Received Mar 7, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEP | HEP B (HEPLISAV-B) | DYNAVAX TECHNOLOGIES CORPORATION | UNK | — | — |
| HEP | HEP B (ENGERIX-B) | GLAXOSMITHKLINE BIOLOGICALS | UNK | Y014323 | — |
Heplisav-B on October 21st 2024 and a dose of Engerix-B on January 24th 2025.; This non-serious case was reported by a nurse via call center representative and described the occurrence of interchange of vaccine products in a 32-year-old male patient who received HBV (Engerix B) (batch number Y014323, expiry date 12-FEB-2027) for prophylaxis. Co-suspect products included Hepatitis b vaccine rHBsAg (yeast) (Heplisav b) for prophylaxis. On 24-JAN-2025, the patient received Engerix B. On 21-OCT-2024, the patient received Heplisav b. On 24-JAN-2025, an unknown time after receiving Engerix B, the patient experienced interchange of vaccine products (Verbatim: Heplisav-B on October 21st 2024 and a dose of Engerix-B on January 24th 2025.). The outcome of the interchange of vaccine products was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 27-FEB-2025 The nurse mentioned that a patient got Heplisav-B on October 21st 2024 and a dose of Engerix-B on January 24th 2025, which led to interchange of vaccine products.